Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) was established in 1995, formerly known as Impax Pharmaceuticals, Inc., completed the business merger in 2018 and changed its current name to its current name, headquartered in Bridgewater, New Jersey , 5,500 full-time employees, together with its subsidiaries, jointly develop, license, manufacture, sell and distribute generic and specialty pharmaceutical products suitable for various dosage forms and therapeutic fields.
Amneal Pharmaceuticals, Inc. (AMRX):
In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc., a U.S. registered publicly traded generic and specialty drugs company. The US Federal Trade Commission (FTC) stated that the value of the merger was US$1.45 billion and required the two companies to divest certain listed products and development projects as conditions for approval. The merger was completed in May 2018. The original IPXL stock code was closed on Nasdaq on May 4, and AMRX stock was traded on the New York Stock Exchange on May 7. Impax Laboratories, Inc. was established on December 14, 1999 by the reverse merger of the listed companies Global Pharmaceutical Corporation and Impax Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (New York Stock Exchange: AMRX) is a comprehensive specialty pharmaceutical company supported by a strong American generic drug business and a growing brand business. The company’s team will work together to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.
Amneal Pharmaceuticals, Inc. operates through two divisions: Generics (generic drug division) and Specialty (specialty drug division).
- Generics -develops, manufactures and commercializes complex oral solids, injections, ophthalmics, liquids, topical medications, soft capsules, inhalation products and transdermal drugs in multiple therapeutic categories.
- Specialty —— is engaged in the development, manufacturing and sales of brand-name drugs mainly used in central nervous system diseases, endocrine, parasitic infections and other therapeutic fields.
Amneal Pharmaceuticals also provides licensed and owned, niche and mature branded products, as well as Rytary for the treatment of Parkinson’s disease; Zomig for the treatment of migraine; Emverm, a chewable tablet, For the treatment of single or mixed infections of pinworm, whipworm, common roundworm, common hookworm and American hookworm; and Unithroid for the treatment of hypothyroidism.
Amneal Pharmaceuticals sells its products through wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies. It has operations in the United States, India, Ireland and internationally.
Amneal Pharmaceuticals Business:
As of July 2019, Amneal operates seven research and development centers (R&D) in the United States, India and Ireland. According to the company, 10% of net revenue is used for research and development.
After the merger of Impax, it is reported that Amneal is the fifth largest manufacturer of generic drugs in the United States. Its generic drug portfolio includes more than 200 product lines, 149 ANDAs submitted to the FDA and 135 projects under development at the time.
The company’s R&D activities in the field of biosimilars include cooperation with Adello Biologics in 2017 (for the joint development of Neuupogen and Neuasta biosimilars) and cooperation with mAbxience in 2018 (for the development of Avastin biosimilars).
2. Pharmaceutical products
Amneal’s generics division focuses on a wide range of therapeutic areas, including solid oral dosage form products and alternative dosage form products. The company’s professional pharmaceutical department focuses on the development of proprietary branded medicines for the treatment of central nervous system diseases, endocrine diseases and other selected specialized fields. The department commercializes several brands of medicines, including Rytary (used to treat Parkinson’s disease in a sustained-release oral capsule formulation), Unithroid (used to treat hypothyroidism), and Emverm (used to treat certain gastrointestinal tracts). Infection) and Zomig nasal spray (for acute treatment). Migraine. As of July 2019, the company has ten production sites and seven research and development sites in the United States, Ireland and India.
In 2020, when the U.S. government requested immediate availability of it as a potential therapeutic agent for COVID-19 , Amneal accelerated the production of hydroxychloroquine sulfate.
Amneal Pharmaceuticals, Inc. (AMRX) History:
- Amneal Pharmaceuticals was founded in 2002 by brothers Chirag and Chintu Patel. The company manufactured its first Rx product in 2005 and obtained its first ANDA approval in 2006.
- In 2007, the company from Mylan to buy five stripped drugs (Mylan), Mylan forced to sell these drugs as part of its acquisition of Merck part (Merck KGaA) generics sector.
- After acquiring the regional distributor Akyma Pharmaceuticals in Glasgow, Kentucky in 2007, Amneal launched its own product label.
- In 2008, with the development of the Gujarat R&D center, the company expanded to India. Between 2010 and 2016, the United States continued to expand in New Jersey, New York and Kentucky.
- As of 2017, the company through a series of acquisitions (including from Pfizer (Pfizer), Ata Davis (Actavis) and Kier Cote Warner (Warner Chilcott) and other acquired assets) expanded its physical footprint and product base.
- In 2018, Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. merged to form Amneal Pharmaceuticals, Inc. The newly listed AMRX shares were listed and traded on the New York Stock Exchange on May 7, 2018.
- While merging with Impax, Amneal acquired Gemini Laboratories for US$117 million, including Unithroid, Gemini’s main product for the treatment of hypothyroidism.
- In December 2019, Amneal announced that it had reached an agreement to acquire a majority stake in AvKARE, a private label provider of generic drugs in the U.S. federal agency sector. According to the agreement, AvKARE will continue to operate as an independent subsidiary of Amneal.
- As of June 2020, co-founders Chirag and Chintu Patel serve as the company’s co-CEOs, and Paul Meister serves as chairman.